MENU
HD Reach
1004 Dresser Ct, Suite 107
Raleigh, NC 27609

Monday through Friday 9 AM - 5 PM

HD Reach
1004 Dresser Ct, Suite 107
Raleigh, NC 27609

Monday through Friday 9 AM - 5 PM

Medical Care

Current Clinical Trials

Clinical trials for Huntington’s Disease often vary. If you can’t find a trial you’re looking for or one that interests you, please bookmark this page and check back often for updates.

Enroll-HD Study

Enrollment is open.

Study Sponsor: Huntington Study Group, Center for Huntington’s Disease International
Phase: Observational
Clinical Sites in NC: Duke, Wake Forest
Website: http://enroll-hd.org/

Enroll-HD is a worldwide observational study for Huntington’s disease families. It will monitor how the disease appears and changes over time in different people, and is open to people who either have HD or are at-risk as well as their family members and caregivers. Enroll-HD is a prospective observational study, meaning it tracks people over time, rather than asking them to recall how their symptoms have changed. Enroll-HD is a platform. The idea is that this one study will make all other HD research easier, speeding up the process of developing new drugs and other treatments that really work.

The goal of Enroll-HD is to build a truly global database of clinical data and biological samples that will accelerate research worldwide. All research participants and clinical sites currently taking part in the REGISTRY and COHORT studies are welcome and encouraged to continue into the new unified Enroll-HD initiative. For more information see the CHDI webpage for Enroll HD and see the Enroll HD brochure.

Study Locations and Contact Information:
Research Coordinator: Christine O’Neill, CRCC
Wake Forest University Baptist Medical Center
Winston Salem, NC
336-716-8611

Research Coordinator: Peggy Perry-Trice 
Duke Movement Disorder Center
Durham, NC
919-684-0865


LEGATO-HD Trial

Enrollment is closed. Study still in progress.

Study Sponsor: Teva Pharmaceuticals
Phase: Phase II, Safety
Clinical Sites in NC: None
Website: http://huntingtonstudygroup.org/current-clinical-trials/legato-hd-trial/

The purpose of the LEGATO-HD trial is to see what effect different doses of an investigational drug called laquinimod may have on people with Huntington’s disease (HD) after 12 months of administration. You may be eligible to participate in the study if you are between the ages of 18 and 55 and have HD.


SIGNAL Trial

Enrollment is closed. Study still in progress.

Study Sponsor: Vaccinex Pharmaceuticals
Phase: Phase II, Safety and Efficacy
Clinical Sites in NC: Duke, Wake Forest
Website: http://huntingtonstudygroup.org/current-clinical-trials/signal-trial/

The SIGNAL trial is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody in people with late prodromal or early manifest Huntington’s disease (HD). This is a different class of drug than any other drug used in previous HD clinical trials. Monoclonal antibodies are more specific than most other drugs because they only bind to and neutralize their desired target.


HD Clarity

Enrollment to begin Fall 2017.

Study Sponsor: Center for Huntington's Disease International
Phase: Biorepository
Clinical Sites: Wake Forest
Website: http://hdclarity.net/

As part of the ENROLL-HD Study, subjects have the option of donating blood for a repository to be used for HD Research. HD Clarity is similar, except cerebrospinal fluid (CSF) will be collected. Multiple sites will be collecting CSF for a repository to facilitate therapeutic development for HD. Like ENROLL, study participants can come from all over the spectrum (Early Premanifest, Late Premanifest, Early HD, Moderate HD, Advanced HD, and Controls). 


WAVE – WHIP

Enrollment to begin Summer 2017.

Study Sponsor:  Wave Life Sciences
Phase:  Phase Ib-2a, Safety and Tolerability Study
Clinical Sites in NC:  Wake Forest            
Website:  http:// www.wavelifesciences.com

The purpose of the study is to find out if the investigational drug WVE-120101 is safe and if it will reduce the production of the mutant huntingtin protein (mHTT).  The intent is that if in reducing or removing the mutant protein (mHTT), there will be an improvement in the symptoms of HD.  The study will measure the safety and tolerability of the new drug and assess the effect of the drug on signs and symptoms of HD.  


Didn't find the clinical trial you were looking for? 

Click on this link for more information:

HD Trialfinder

A search tool to identify all clinical trials that match your profile and the closest trial sites, and updates you when new studies open that match your profile.

Request a Contact or Search by Phone
1-866-890-6612
Monday - Friday: 9:00 am - 6:00 pm ET

HD Trialfinder On-Line Search


HD Reach
1004 Dresser Ct, Suite 107
Raleigh, NC 27609

Monday through Friday 9 AM - 5 PM

© HD Reach